# A Study of CriPec® Docetaxel Given to Patients With Solid Tumours

> **NCT02442531** · PHASE1 · COMPLETED · sponsor: **Cristal Therapeutics** · enrollment: 33 (actual)

## Conditions studied

- Cancer
- Metastatic Cancer
- Solid Tumors

## Interventions

- **DRUG:** CriPec® docetaxel

## Key facts

- **NCT ID:** NCT02442531
- **Lead sponsor:** Cristal Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442531, "A Study of CriPec® Docetaxel Given to Patients With Solid Tumours". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02442531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*